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A B S T R A C T
Purpose
Although the incidence and mortality of colon cancer in the United States has declined over the
past two decades, blacks have worse outcomes than whites. Variations in treatment may
contribute to mortality differentials.
Methods
Patients diagnosed with stage III colon cancer were randomly sampled from the SEER program
from the years 1990, 1991, 1995, 2000, 2005, and 2010. Patients were categorized as
non-Hispanic white (n  835) or black (n  384). Treatment data were obtained from a review of
the medical records, and these data were verified through contact with the original treating
physicians. Log-binomial regression models were used to estimate the association between race
and receipt of adjuvant chemotherapy. Effect modification by insurance was assessed with use of
single referent models.
Results
Receipt of adjuvant chemotherapy among both white and black patients increased from the period
encompassing the years 1990 and 1991 (white, 58%; black, 45%) to the year 2005 (white, 72%;
black, 71%) and then decreased in the year 2010 (white, 66%; black, 57%). There were marked
racial disparities in the time period of 1990 to 1991 and again in 2010, with black patients less likely
to receive adjuvant chemotherapy as compared with white patients (risk ratio [RR], .82; 95% CI,
.72 to .93). For black patients, receipt of adjuvant chemotherapy did not differ across insurance
categories (RR for private insurance, .80; 95% CI, .69 to .93; RR for Medicare, .84; 95% CI, .69 to
1.02; and RR for Medicaid, .84; 95% CI, .69 to 1.02), although a larger proportion had Medicaid in
all years of the study as compared with white patients.
Conclusion
The chemotherapy differential narrowed after the time period of 1990 to 1991, but our findings
suggest that the disparity reemerged in 2010. Recent decreases in chemotherapy use may be
due, in part, to the economic downturn and an increase in Medicaid coverage.
J Clin Oncol 33:2530-2536. © 2015 by American Society of Clinical Oncology
INTRODUCTION
The incidence and mortality of colon cancer in the
United States has declined over the past two decades,
but this decline has been less for black patients than
for white patients. Colon cancer disproportionately
affects blacks, who experience continually higher in-
cidence and mortality than whites. From 1975 to
2011, the average incidence rates were 39.7 and 46.4
per 100,000 for whites and blacks, respectively.1
Mortality rates during the same period were 21.8 per
100,000 for whites and 27.2 per 100,000 for blacks.1
Although mortality rates have decreased for each
stage among both whites and blacks, the decreases
have been smaller for blacks.2 For example, between
1985 and 2008, relative mortality decreased by 49%
among whites with regional stage disease compared
with a 34% decrease among blacks.3 Racial dispari-
ties in colon cancer outcomes are partly attributable
to differences in risk factors,4-6 screening and early
detection,7-9 follow-up of abnormalities,10 and tu-
mor biology11-15; however, variations in treatment
may also contribute to mortality differentials.
Adjuvant chemotherapy is recognized as stan-
dard guideline care for patients who have been
newly diagnosed with stage III colon cancer. Early
randomized trials showed significant reductions
in the risk of cancer recurrence and mortality among
patients with stage III disease treated with 5-
fluorouracil (5-FU) and levamisole following
surgery.16-18 These results, combined with the rec-
ommendations of the National Institutes of Health
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Consensus Development Conference on Adjuvant Therapy for Pa-
tients with Colon and Rectal Cancer,19 led to an increased use of
adjuvant chemotherapy in the 1990s.20,21 Several chemotherapy regi-
mens have since emerged as acceptable standards of care for patients
with stage III colon cancer treated with surgery. Adjuvant 5-FU,
leucovorin,22-24 and, more recently, oxaliplatin and capecitabine
have been shown to provide additional survival benefits.25-29 Cur-
rent guidelines recommend treatment regimens such as 5-FU
and leucovorin combined or with the addition of oxaliplatin
(FOLFOX), capecitabine combined with oxaliplatin (CapeOx), or
single-agent capecitabine.30
Previous studies report racial disparities in the receipt of adjuvant
chemotherapy among patients with stage III colon cancer, with black
patients less likely than white patients to receive chemotherapy.31-33
The extent of this disparity over time and in different settings remains
unknown. The purpose of this study was to examine patterns of
adjuvant chemotherapy use among non-Hispanic whites and blacks
in a population-based sample of patients with stage III colon cancer.
We focused on treatment during 1990, 1991, 1995, 2000, 2005, and




Patients diagnosed with stage III colon cancer were sampled from the
National Cancer Institute’s (NCI) population-based program of SEER cancer
registries (n  1,898). The SEER registries routinely collect information on
demographics, diagnosis, tumor characteristics, and treatment for all persons
diagnosed with cancer who reside in defined geographic regions, which in-
clude approximately 28% of the US population. Adjuvant therapy adminis-
tered in the outpatient setting is often under-ascertained by the SEER
registries; therefore, the NCI annually conducts patterns of care (POC) studies
on a sample of persons with select cancers to assess the use of adjuvant
therapies as initial treatment in community settings. Patients with stage III
colon cancer in participating SEER registries were eligible for POC studies in
1990, 1991, 1995, 2000, 2005, and 2010. Stage III included any T1 to T4 tumors
with regional lymph-node involvement. Patients were stratified by registry,
sex, age, and race or ethnicity, and a random sample was taken from within
each strata. There was oversampling by race in 1995, 2000, 2005, and 2010.
Patients were ineligible if they were younger than 20 years, previously diag-
nosed with cancer (excluding nonmelanoma skin cancer), diagnosed at au-
topsy or on death certificate only, or diagnosed with a synchronous cancer.
Patient medical records were abstracted for chemotherapy agents and
dates of treatment following diagnosis. Treating physicians were contacted and
asked to verify specific chemotherapeutic agents received as part of initial
therapy. Patients for whom chemotherapy was recommended or given were
considered to have received adjuvant chemotherapy. Patients who refused
chemotherapy (n  32) were not considered to have received chemotherapy.
We excluded patients who did not undergo cancer-directed surgery (n  8),
those with unknown or missing chemotherapy agents (n  41), those with
unknown or no health insurance (n  95), or those who identified as a race or
ethnicity other than non-Hispanic white or black (n  535).
Covariates
Patient demographic (age, sex, marital status, and race) and diagnosis
and tumor characteristics (date of diagnosis, stage, and anatomic location)
were obtained from routinely collected SEER registry data. Race or ethnicity
was categorized as non-Hispanic white (white) or non-Hispanic black (black).
Patient comorbidities, tumor grade, and histology were abstracted from the
medical record; comorbidity was assessed with use of the Charlson comorbid-
ity index.34 Insurance reported on the medical record was classified into
mutually exclusive groups of private insurance (including health maintenance
organizations and military coverage), any Medicaid, or Medicare only (ie,
patients with Medicare and private insurance were classified as having private
insurance). Each registry identified hospital characteristics, including hospital
type (private, government, or nonprofit), an approved residency training
program, and total bed size. High-risk tumor features, including bowel ob-
struction (complete or partial), inadequately sampled lymph nodes ( 12)
during resection of the primary tumor, and positive surgical margins, were
abstracted from the medical record.
Data Analysis
Weighted proportions were used to examine trends in the receipt of
adjuvant chemotherapy and the proportion of patients who received common
chemotherapy agents and combination chemotherapy regimens. Sample
weights were calculated as the inverse of the sampling proportion for each
sampling stratum. Log-binomial regression models with stratum-specific
sample weights were used to estimate the association of race and insurance
with receipt of adjuvant chemotherapy in the total population as well as among
a subset of patients considered optimal chemotherapy patients. Optimal che-
motherapy patients were defined as patients younger than 75 years of age who
have a comorbidity score of 1 or less. Models were adjusted for age at diagnosis,
comorbidity, year of diagnosis, race (insurance model), and insurance (race
model). Adjusted associations between race, insurance, and receipt of adjuvant
chemotherapy are presented as risk ratios and 95% confidence intervals. We
also report the marginal probability of receiving adjuvant chemotherapy by
race and insurance groups.
We evaluated effect measure modification by insurance type with use of
single referent models with indicator terms. White patients with private insur-
ance served as the referent group. Cross-product terms of race with Medicare
and race with Medicaid were included in a log-binomial regression model to
determine whether the estimated association between race and receipt of
chemotherapy differs among patients covered under Medicare or Medicaid.
We compared model fit of the lower-order model with the product-term
model using the quasi-likelihood under the independence model criterion for
generalized estimating equations models.35 All analyses were conducted with
use of SAS version 9.3 (SAS/STAT User’s Guide, version 9.3, 2011; SAS Insti-
tute, Cary, NC) and SUDAAN version 11.0.1 (Research Triangle Institute,
Research Triangle Park, NC).
RESULTS
Characteristics of the study population (n  1,219) by race are shown
in Table 1. Overall, 64.6% of patients received adjuvant chemotherapy
during the study period. Receipt of chemotherapy increased among
white and black patients from the years 1990 and 1991 (white, 58.2%;
black, 45.2%) to the year 2005 (white, 71.8%; black, 71.4%) and
decreased in 2010 (white, 66.3%; black, 56.9%; Fig 1). There was no
difference in the proportion of white and black patients who received
adjuvant chemotherapy in 1995 (white, 58.3%; black, 57.9%), 2000
(white, 66.1%; black, 66.2%) and 2005, but there were marked dispar-
ities in the period encompassing 1990 and 1991 and in the year 2010.
Among optimal chemotherapy patients (ie, patients younger than 75
years of age who had a comorbidity score of 1 or less), a smaller
proportion of black patients received chemotherapy in all study years
as compared with whites (Fig 2). Receipt of adjuvant chemotherapy in
this subgroup increased for whites after 1995 (72.5%) and continued
to increase through 2005 (92.1%) but decreased in 2010 (87.0%). The
proportion of optimal chemotherapy black patients who received
adjuvant chemotherapy increased from the time period of 1990 and
1991 (57.9%) to the year 2005 (84.1%) and decreased in 2010 (67.2%).
In the log-binomial regression models, black race was associated
with lower receipt of adjuvant chemotherapy (RR, .82; 95% CI, .72 to
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.93) after adjusting for age, comorbidity, insurance, and year of diag-
nosis (Table 2). The relative risk was similar (RR, .84; 95% CI, .75 to
.95) in the analysis limited to optimal chemotherapy patients. There
was no association of insurance with receipt of chemotherapy in the
overall analysis or the analysis of optimal chemotherapy patients.
Insurance did not modify the effect of race on receipt of adjuvant
chemotherapy (Table 3). In the single referent models, risk ratios for
the receipt of chemotherapy were similar for black patients across all
strata of insurance (RR for private insurance, .80; 95% CI, .69 to .93;
RR for Medicare, .84; 95% CI, .69 to 1.02; RR for Medicaid, .84; 95%
CI, .69 to 1.02) compared with white patients with private insurance.
Stratum-specific risk ratios for the association of race and receipt of
adjuvant chemotherapy were similar (RR for private insurance, .80;
95% CI, .69 to .93; RR for Medicare, .84; 95% CI, .68 to 1.05; RR for
Medicaid, .93; 95% CI, .69 to 1.24). Model fit statistics indicated the
lower-order term model (ie, main effects model) fit the data better
than the model with cross-product terms (quasi-likelihood under the
independence model criterion 12087.8 v 12100.9). Similar results were
observed among optimal chemotherapy patients (data not shown).
White and black patients who had been diagnosed in 2005 and
2010 and were treated with chemotherapy received similar chemo-
therapy agents (Table 4). There were no significant differences in the
proportion of chemotherapy-treated patients who received any 5-FU
(white, 90.1%; black, 83.0%), oxaliplatin (white, 73.9%; black,
76.4%), or capecitabine (white, 14.5%; black, 16.2%). The majority of






No. Weighted % No. Weighted %
Sociodemographic
Sex
Male 413 47.4 181 42.5
Female 422 52.6 203 57.5
Age at diagnosis, years
Mean (SE) 70.4 (0.59) 64.8 (0.79)
 55 108 12.0 92 21.3
55-64 158 20.8 96 27.1
65-74 226 22.9 104 27.5
75-79 137 15.8 39 11.0
 80 206 28.4 53 13.2
Health insurance
Private/HMO/VA/Other 668 78.6 236 61.9
Medicare (only) 131 16.6 79 21.1
Medicaid (any) 36 4.8 69 17.0
Marital status
Married 508 56.2 155 40.2
Not married 310 41.9 218 56.7
Unknown 17 1.9 11 3.1
Comorbidity score
0 608 70.4 248 66.1
1 181 23.8 101 25.7
 2 46 5.8 35 8.2
Tumor
Year of diagnosis
1990/1991 409 21.6 44 14.5
1995 102 10.3 89 8.9
2000 88 16.9 57 13.9
2005 145 26.6 97 31.1
2010 91 24.5 97 31.7
Histologic grade
Well/moderately differentiated 560 68.3 281 74.0
Poorly/undifferentiated 232 28.4 81 21.2
Unknown 43 3.3 22 4.8
Bowel obstruction
No 560 69.1 256 67.4
Yes 239 28.9 110 29.2
Unknown 36 2.0 18 3.5
Inadequately sampled lymph
nodes ( 12)
No 414 59.5 236 62.4
Yes 382 37.9 137 34.8
Unknown 39 2.6 11 2.8
Positive margins
No 689 86.0 359 92.7
Yes 33 5.7 10 3.9
Unknown 113 8.4 15 3.4
Hospital/Provider
Hospital type
Private 67 8.6 27 7.3
Government 121 12.5 56 12.7
Nonprofit 642 77.7 301 80.0
Unknown 5 1.2 0
Teaching hospital
No 439 51.7 147 43.1
Yes 386 47.3 237 56.9
Unknown 10 1.0 0
(continued in next column)







No. Weighted % No. Weighted %
Total bed size
 200 227 26.3 73 17.9
200-399 366 42.4 149 40.5
 400 234 30.4 162 41.6
Unknown 8 .8 0
NOTE. Column percentages displayed in table.
Abbreviations: NH, non-Hispanic; HMO, health maintenance organization;
VA, Veterans Affairs.






























Fig 1. Proportion of patients with stage III colon cancer who received adjuvant
chemotherapy by year of diagnosis and race (N  1,219). NH, non-Hispanic.
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patients received FOLFOX (white, 69.8%; black, 68.0%), and a grow-
ing number of patients received capecitabine, either alone (white,
5.2%; black, 4.6%) or in combination with oxaliplatin (white, 2.8%;
black, 4.4%).
DISCUSSION
Our results demonstrate significant racial differences in the receipt of
adjuvant chemotherapy among patients with stage III colon cancer
over a 20-year time period. Although the gap in the proportion of
white and black patients who received chemotherapy narrowed after
the period encompassing 1990 and 1991, the disparity reemerged in
2010. Chemotherapy use decreased among all patients who had been
diagnosed in 2010, but the decrease was more substantial in blacks
(57%) compared with whites (66%). Black patients in this study were
younger than white patients (mean age, 65 v 70 years), and both
groups had similar high-risk tumor features (eg, histologic grade, and
inadequately sampled lymph nodes). Yet, a smaller proportion of
blacks received chemotherapy. There were even larger differences in
the proportion of black and white patients who received chemother-
apy among the subgroup of optimal chemotherapy patients who were
younger and had a low or no comorbidity score. In this subgroup, 87%
of white patients received chemotherapy in 2010 as compared with
only 67% of blacks.
These findings suggest that differences in chemotherapy receipt
are likely not the result of differences in patient or tumor characteris-
tics. Rather, the racial disparity in chemotherapy receipt in 2010 may
reflect differences in the ability to pay for cancer treatment during the
economic downturn that followed the 2008 financial crisis. National
expenditures for colorectal cancer in the year following diagnosis were
among the highest of all major cancer sites in 2010.36 As the costs of
cancer care have continued to increase rapidly, an emerging body of
literature reports that a growing number of patients with cancer and
cancer survivors are experiencing economic problems (eg, high insur-
ance copayments, out-of-pocket costs, and bankruptcy) related to
cancer treatment.37-42 Black Americans were disproportionately af-
fected by the 2008 recession, and 28% reported losing a job as a
result.43 Unemployment remained high in 2010, with 16.0% and 8.7%
unemployment rates among blacks and whites, respectively.44 In a
recent study of adult patients with cancer and cancer survivors
from the 2010 National Health Interview Survey, one-third of all
participants — and nearly half of non-Hispanic blacks — reported
cancer-related financial problems.39 Other studies show that minority
patients with breast, prostate, and lung cancers45-47 experience higher
treatment costs as compared with whites.48 Increased unemployment
and income loss during and shortly after the recession may have
exacerbated the impact of cancer-treatment costs on the financial
burden of patients. The inequitable economic impact of the recession
among black patients may have contributed to the lower receipt of
chemotherapy that we observed in 2010.
The introduction of oxaliplatin and capecitabine may also have
resulted in some patients forgoing chemotherapy in 2010. The cost of
cancer therapy plays an important role in treatment decisions, and
cancer patients with an increased financial burden are more likely to
delay or forgo medical care.39,48 On average, the wholesale price of
chemotherapy regimens containing 5-FU and leucovorin (monthly,
weekly, or biweekly) ranges from $60 to $300,49 while total costs of
5-FU and oxaliplatin can cost upward of $25,000.50 The average
wholesale price of one cycle of capecitabine ranges from $2,600 to
$3,500.51 The increased out-of-pocket cost of these regimens may































Fig 2. Proportion of optimal chemotherapy patients with stage III colon cancer
who received adjuvant chemotherapy by year of diagnosis and race (n  739).
NH, non-Hispanic.
Table 2. Log-Binomial Regression Analysis for the Association of Race and Insurance With Receipt of Adjuvant Chemotherapy Among All Patients With Stage III
Colon Cancer and Optimal Chemotherapy Patients With Stage III Colon Cancer
Variable
All Patients With Stage III Disease (N  1,219)
Patients With Stage III Disease Receiving Optimal
Chemotherapy (n  739)
Adjusted RR 95% CI Predicted Marginal Adjusted RR 95% CI Predicted Marginal
Race/ethnicity
NH white 1.00 0.66 1.00 0.85
NH black 0.82 0.72 to 0.93 0.52 0.83 0.73 to 0.94 0.71
Insurance†
Private 1.00 0.64 1.00 0.84
Medicare (only) 1.00 0.76 to 1.13 0.67 0.98 0.85 to 1.13 0.81
Medicaid (any) 0.93 0.89 to 1.12 0.61 0.93 0.76 to 1.13 0.80
NOTE. Patients receiving optimal chemotherapy defined as patients younger than 75 years of age and with a comorbidity score of one or less.
Abbreviations: NH, non-Hispanic; RR, risk ratio.
Adjusted for age at diagnosis, comorbidity score, insurance, and year of diagnosis.
†Adjusted for race and ethnicity, age at diagnosis, comorbidity score, and year of diagnosis.
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Although the cost of oxaliplatin may have led some patients to
forgo treatment, among patients in our study who did receive chemo-
therapy, more than 80% were treated with oxaliplatin in 2010. The
proportion of white and black patients who received oxaliplatin was
similar, although white patients were, on average, older than black
patients. The racial differences in age are important because current
guidelines recommend against treatment with oxaliplatin for patients
older than 70 years.30 If physicians follow practice guidelines, a higher
proportion of black patients are eligible for oxaliplatin and may face
treatment decisions related to the costs of oxaliplatin, potentially in-
creasing the disparity in chemotherapy use. It is important to monitor
the extent to which disparities have persisted since 2010 as the types of
agents and their costs continue to change.52
The role of insurance in the receipt of adjuvant chemotherapy is
less clear. We expected differences in chemotherapy receipt to dissi-
pate when comparing white and black patients with the same type of
insurance, but the modification analysis showed that disparities ex-
isted similarly in all levels of insurance coverage (private insurance,
Medicare, and Medicaid) over the entire study period. Racial dispari-
ties within insurance categories may be the result of differences by race
in the underlying health status of patients, provider recommendations
or patient preferences regarding treatment, or variability in the burden
of cost-sharing from premium and deductible expenses. We also ob-
served that a smaller proportion of white and black patients who had
Medicaid insurance received chemotherapy in 2010 than did white
patients with private insurance. Medicaid enrollment rose by nearly 6
million per month53 during the recession, and approximately 27% of
blacks and 11% of whites were covered under Medicaid (including
children) across the country.43 In our study, a greater proportion of
black patients than white patients had Medicaid insurance in all study
years, and, in 2010, 21% of blacks had Medicaid insurance as com-
pared with just 5% of whites (Appendix Fig A1, online only). The
greater pressure put on Medicaid during the recession may have led to
increased coverage denials that negatively affected receipt of standard
care. In a study of financial hardships faced by patients with colorectal
cancer, the proportion of patients who experienced coverage denials
was highest among Medicaid enrollees. Denials for chemotherapy,
most often capecitabine, accounted for almost half of all insurance
denials reported.54 We did not have sufficient power to examine the
effect of race within each insurance category by year, but the dispro-
portionate number of black patients who enrolled in Medicaid also
may have contributed to the disparity in 2010.
Our findings are consistent with early studies of SEER-Medicare
data, which showed black patients with colon cancer were less likely to
receive chemotherapy as compared with white patients.31-33 In a study
of patients with stage III colon cancer diagnosed within the time frame
of 1992 to 1996, although black and white patients were equally likely
to consult with a medical oncologist, black patients less often received
chemotherapy.31 Only half of this disparity was explained by differ-
ences in patient sociodemographics, severity of illness, and tumor
characteristics. A similar study found that a smaller proportion of
black patients received chemotherapy as compared with whites, even
among patients with no comorbidities.32 There is varying evidence
concerning whether treatment disparities have diminished in later
time periods. Our finding that chemotherapy receipt was similar for
black and white patients in 1995, 2000, and 2005 is consistent with
prior research that suggests that the treatment disparity noted in the
early 1990s decreased over time.33,55,56 Others have found a persistent
disparity through the mid-2000s.57-59 Differences in our results and
those of others may be because of differences in study populations (eg,
patient age or insurance type).
Limitations of our study include our inability to collect informa-
tion on patient and physician preferences, which may further explain
patterns in chemotherapy use during the study period. Patients with
no insurance were excluded from the study and may have experienced
worse outcomes; however, as there were few uninsured patients,
Table 3. Single-Referent and Stratum-Specific RRs for the Association of Race With Receipt of Adjuvant Chemotherapy Across Strata of








White, private 66.8 1.00
Black, private 64.6 0.80 0.69 to 0.93 0.80 0.69 to 0.93
White, Medicare 58.7 0.99 0.87 to 1.13
Black, Medicare 52.8 0.84 0.69 to 1.02 0.84 0.68 to 1.05
White, Medicaid 60.2 0.91 0.72 to 1.14
Black, Medicaid 58.6 0.84 0.69 to 1.02 0.93 0.69 to 1.24
NOTE. RR adjusted for age at diagnosis, comorbidity, and year of diagnosis.
Abbreviation: RR, risk ratio.
Proportion weighted by sampling fraction.
Table 4. Receipt of Select Chemotherapy Agents and Combination
Chemotherapy Regimens by Race Among Patients With Stage III
Colon Cancer Who Were Diagnosed in 2005 and 2010 and Treated With
Adjuvant Chemotherapy
Chemotherapy
NH White (n  159) NH Black (n  130)
Weighted % SE Weighted % SE
Agents (any)†
FU 90.1 2.69 83.0 3.27
Oxaliplatin 73.9 4.70 76.4 3.97
Capecitabine 14.5 3.34 16.2 3.52
Regimens
FU  leucovorin 14.8 3.80 7.5 2.81
FOLFOX 69.8 4.82 68.0 4.00
Capecitabine alone 5.2 2.29 4.6 1.60
CapeOx 2.8 1.15 4.4 1.99
Abbreviations: FU, fluorouracil; CapeOx, capecitabine and oxaliplatin;
FOLFOX, fluorouracil, leucovorin, and oxaliplatin; NH, non-Hispanic.
Proportion weighted by sampling fraction.
†Chemotherapy agents not mutually exclusive.
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the results would not be likely to change appreciably. A strength of
our study is the complex sampling scheme that resulted in compa-
rable characteristics of white and black patients included in the
analysis. Many previous studies have been limited by inherent
differences in the study population. Patients included in our study
all had stage III disease and were sampled by sex, age, and registry
and then oversampled by race to obtain more stable estimates.
Specific chemotherapy agents and treatment dates were abstracted
from patient medical records and verified by treating physicians,
which limits the possibility that we overestimated the proportion
of patients who received chemotherapy.
As insurance coverage and health policy continue to change with
the introduction of the Affordable Care Act, it is important to under-
stand the degree to which disparities in the receipt of cancer treatment
will remain. Although health care reform will allow for universal
insurance coverage, there will be differences in the level of benefits and
out-of-pocket costs. Differences in reimbursement rates to providers
may affect the number of physicians who are willing to accept and treat
patients with certain health insurance policies, such as Medicaid. On
average, Medicaid pays 25% less to physicians than Medicare pays.60
Acceptance of new patients enrolled in Medicaid is less in states with
lower Medicaid fees as compared with Medicare reimbursement than
it is in states with higher Medicaid fees,61 and a substantially smaller
proportion of physicians in low-fee states treat new patients enrolled
in Medicaid as compared with the proportion of physicians in high
fee-states. With a limited number of oncologists and an increasing
number of patients with cancer, the ability of patients to find a physi-
cian willing to accept a particular type of insurance may continue to
influence receipt of chemotherapy. Such changes may ultimately re-
sult in financial resources playing as important a role as clinical rec-
ommendations in treatment decisions and access to care.
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Fig A1. Proportion of patients with stage III colon cancer with Medicaid by year of diagnosis and race (N  1,219). NH, non-Hispanic.
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